RECENT ADVANCES IN ENDOCRINOLOGY: Pioglitazon

Pioglitazone is the only freely available member of the thiazolidinedione (TZD) or glitazone group of oral antidiabetic drugs (OADs). Other drugs in the class: troglitazone, englitazone and darglitazone have been withdrawn from the market, or discontinued from clinical development Rosiglitazone, which was banned in many countries due to cardiovascular safety concerns, has recently been removed from the risk evaluation and mitigation strategy (REMS) list by the United States Food and Drugs Administration (FDA).